Yoffe Investment Management LLC Takes $462,000 Position in GSK plc (NYSE:GSK)

Yoffe Investment Management LLC bought a new stake in shares of GSK plc (NYSE:GSK - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 13,657 shares of the pharmaceutical company's stock, valued at approximately $462,000.

Other large investors also recently added to or reduced their stakes in the company. Indiana Trust & Investment Management Co raised its stake in GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust acquired a new stake in GSK during the 4th quarter valued at $26,000. Sierra Ocean LLC acquired a new stake in GSK during the 4th quarter valued at $32,000. Parkside Financial Bank & Trust grew its holdings in shares of GSK by 470.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock valued at $34,000 after acquiring an additional 818 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of GSK during the 4th quarter valued at $40,000. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Up 2.6%

NYSE:GSK traded up $1.03 during trading hours on Friday, reaching $41.03. The company's stock had a trading volume of 7,371,682 shares, compared to its average volume of 4,872,127. The company has a market cap of $84.65 billion, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. GSK plc has a one year low of $31.72 and a one year high of $45.01. The business's 50-day moving average is $37.33 and its 200-day moving average is $36.15. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. GSK had a net margin of 8.13% and a return on equity of 48.59%. The business had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. During the same quarter in the prior year, the business earned $0.43 earnings per share. The firm's revenue for the quarter was up 2.1% on a year-over-year basis. Equities research analysts predict that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be paid a dividend of $0.4216 per share. This represents a $1.69 annualized dividend and a yield of 4.11%. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date is Friday, May 16th. GSK's dividend payout ratio is currently 86.60%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a report on Monday, April 28th. BNP Paribas assumed coverage on shares of GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target on the stock. Wall Street Zen cut shares of GSK from a "buy" rating to a "hold" rating in a report on Friday. Finally, Morgan Stanley assumed coverage on shares of GSK in a report on Wednesday, February 12th. They set an "equal weight" rating on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.